BioSmart KRX:038460KOSDAQ
바이오스마트 · Korean news coverage and regulatory filings, organized.
Articles, 24h0
Articles, 7 days0
DART filings, 7 days0
Articles tracked1since Sep 11
In Q2 2026, BioSmart reported revenue of ₩168bn, up 38.8% year on year, and operating profit of ₩5.1bn. BioSmart (바이오스마트) appeared in 0 Korean news articles and 0 DART filings over the past seven days.
Filing signals Revenue +30% Revenue & profit growth Screener
BioSmart quarterly results consolidated, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q2 2026 | ₩168bn | +38.8% | ₩5.1bn margin 3.1% | ₩2.2bn |
| Q1 2026 | ₩145bn | +29.4% | ₩10.1bn margin 6.9% | ₩7.2bn |
| Q4 2025 derived | ₩124bn | +6.6% | ₩5.1bn margin 4.1% | ₩4.0bn |
| Q3 2025 | ₩126bn | +5.4% | ₩7.6bn margin 6.1% | ₩4.9bn |
| Q2 2025 | ₩121bn | -7.1% | ₩4.2bn margin 3.5% | −₩2.8bn |
| Q1 2025 | ₩112bn | -5.4% | ₩5.6bn margin 5.0% | ₩2.8bn |
| Q4 2024 derived | ₩116bn | +6.4% | ₩7.2bn margin 6.2% | ₩2.4bn |
| Q3 2024 | ₩119bn | +4.4% | ₩3.8bn margin 3.2% | −₩1.5bn |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.
BioSmart top stories 2 weeks, by number of outlets
No story covered by multiple outlets in the past two weeks.